Actively Recruiting
Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-06-26
132
Participants Needed
1
Research Sites
221 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity. The aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity. This is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).
CONDITIONS
Official Title
Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Diagnosis of ADHD according to DIVA 2.0 or DIVA-5
- At least one moderate to severe substance use disorder (excluding tobacco) by DSM-5
- Currently receiving treatment for substance use disorder by a physician or psychologist
- Affiliated with health insurance
- Able to understand and express themselves in French
- Signed informed consent
You will not qualify if you...
- Under 18 years old
- Pregnant or breastfeeding women
- Did not sign the consent form
- Major difficulty understanding or expressing in French
- Severe cognitive impairment
- Acute medical condition preventing assessment or group intervention
- Substance use disorder in a protected environment currently or in last 15 days or expected during study
- Only tobacco use disorder without other substance use disorder
- Under guardianship
- Deprived of liberty or under penal care orders
- Participating in another group psychotherapeutic intervention during study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Fernand Widal, Assistance-Publique - Hôpitaux de Paris
Paris, France, 75010
Actively Recruiting
Research Team
N
Norman Therribout, PhD
CONTACT
R
Romain Icick, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here